BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35286386)

  • 1. The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells.
    Pramanik S; Chen Y; Song H; Khutsishvili I; Marky LA; Ray S; Natarajan A; Singh PK; Bhakat KK
    Nucleic Acids Res; 2022 Apr; 50(6):3394-3412. PubMed ID: 35286386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous oxidized DNA bases and APE1 regulate the formation of G-quadruplex structures in the genome.
    Roychoudhury S; Pramanik S; Harris HL; Tarpley M; Sarkar A; Spagnol G; Sorgen PL; Chowdhury D; Band V; Klinkebiel D; Bhakat KK
    Proc Natl Acad Sci U S A; 2020 May; 117(21):11409-11420. PubMed ID: 32404420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of hnRNP A1 in activating KRAS transcription in pancreatic cancer cells: A molecular mechanism involving G4 DNA.
    Cogoi S; Rapozzi V; Cauci S; Xodo LE
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1389-1398. PubMed ID: 27888145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second Harmonic Generation Interrogation of the Endonuclease APE1 Binding Interaction with G-Quadruplex DNA.
    Fleming AM; Tran R; Omaga CA; Howpay Manage SA; Burrows CJ; Conboy JC
    Anal Chem; 2022 Nov; 94(43):15027-15032. PubMed ID: 36269876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.
    Logsdon DP; Grimard M; Luo M; Shahda S; Jiang Y; Tong Y; Yu Z; Zyromski N; Schipani E; Carta F; Supuran CT; Korc M; Ivan M; Kelley MR; Fishel ML
    Mol Cancer Ther; 2016 Nov; 15(11):2722-2732. PubMed ID: 27535970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human AP-endonuclease (Ape1) activity on telomeric G4 structures is modulated by acetylatable lysine residues in the N-terminal sequence.
    Burra S; Marasco D; Malfatti MC; Antoniali G; Virgilio A; Esposito V; Demple B; Galeone A; Tell G
    DNA Repair (Amst); 2019 Jan; 73():129-143. PubMed ID: 30509560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice.
    Cogoi S; Zorzet S; Rapozzi V; Géci I; Pedersen EB; Xodo LE
    Nucleic Acids Res; 2013 Apr; 41(7):4049-64. PubMed ID: 23471001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival.
    Cardoso AA; Jiang Y; Luo M; Reed AM; Shahda S; He Y; Maitra A; Kelley MR; Fishel ML
    PLoS One; 2012; 7(10):e47462. PubMed ID: 23094050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription.
    Cogoi S; Ferino A; Miglietta G; Pedersen EB; Xodo LE
    Nucleic Acids Res; 2018 Jan; 46(2):661-676. PubMed ID: 29165690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine Oxidation to Sulfenic Acid in APE1 Aids G-Quadruplex Binding While Compromising DNA Repair.
    Howpay Manage SA; Fleming AM; Chen HN; Burrows CJ
    ACS Chem Biol; 2022 Sep; 17(9):2583-2594. PubMed ID: 36037088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Poly [ADP-ribose] Polymerase 1 in Activating the
    Cinque G; Ferino A; Pedersen EB; Xodo LE
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the endoribonuclease active site of human apurinic/apyrimidinic endonuclease 1.
    Kim WC; Berquist BR; Chohan M; Uy C; Wilson DM; Lee CH
    J Mol Biol; 2011 Sep; 411(5):960-71. PubMed ID: 21762700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleotide sequence and DNA secondary structure, as well as replication protein A, modulate the single-stranded abasic endonuclease activity of APE1.
    Fan J; Matsumoto Y; Wilson DM
    J Biol Chem; 2006 Feb; 281(7):3889-98. PubMed ID: 16356936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.
    Shah F; Goossens E; Atallah NM; Grimard M; Kelley MR; Fishel ML
    Mol Oncol; 2017 Dec; 11(12):1711-1732. PubMed ID: 28922540
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Marquevielle J; Kumar MVV; Mergny JL; Salgado GF
    Biomol NMR Assign; 2018 Apr; 12(1):123-127. PubMed ID: 29189986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy.
    Pattanayak R; Barua A; Das A; Chatterjee T; Pathak A; Choudhury P; Sen S; Saha P; Bhattacharyya M
    Eur J Pharm Sci; 2018 Dec; 125():39-53. PubMed ID: 30223034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.